LoginRegister

    Zydus Cadila gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

    Farhat NasimWritten by Farhat Nasim   |  
    Zydus Cadila gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

    The company said Esomeprazole belongs to the group of medicines termed as proton pump inhibitors.


    New Delhi: Zydus Cadila has received final approval from the US health regulator to market Esomeprazole Magnesium delayed-release capsules, used to treat acid reflux. The approval has been granted in the strengths of 25 mg and 40 mg, the company said in a BSE filing.


    Zydus Cadila said the drug will be produced at the group's formulations manufacturing facility at Ahmedabad.


    The company said Esomeprazole belongs to the group of medicines termed as proton pump inhibitors.


    Also Read: Zydus Cadila gets USFDA nod for Chlorthalidone tablets to treat high BP


    Esomeprazole reduces the amount of acid secreted by the stomach.




    It is used to treat the symptoms of gastroesophageal reflux disease, to reduce the risk of stomach ulcers in some people taking pain medicines, to treat patients with a stomach infection (Helicobacter pylori) along with certain antibiotics and long-term treatment of conditions where the stomach makes too much acid.


    The group has more than 266 approvals and so far filed over 350 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.


    Also Read: CDSCO approves Zydus, SIFI pact to launch Intraocular Lenses in India

    acid refluxacidity drugANDAantibioticsBSEEsomeprazoleEsomeprazole capsulesEsomeprazole MagnesiumgastroesophagealHelicobacter pyloriinhibitorsproton pumpstomach ache drugUSFDAzydusZydus Cadila
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X